pharma news, views and analysis

in News
New combination trial firms up Venclexta’s prospects in AML
March 24, 2020 Share
X
New combination trial firms up Venclexta’s prospects in AML
https://pharmaphorum.com/news/new-combination-trial-firms-up-venclextas-prospects-in-aml/
in News
AZ’s immunotherapy combo fails in phase 3 lung cancer trial
March 17, 2020 Share
X
AZ’s immunotherapy combo fails in phase 3 lung cancer trial
https://pharmaphorum.com/news/azs-immunotherapy-combo-fails-in-phase-3-lung-cancer-trial/

Latest News

Merck, Pfizer’s Bavencio flunks head and neck cancer trial

Merck KGaA and Pfizer’s checkpoint inhibitor Bavencio has failed a phase 3 trial in head and neck cancer,

Merck, Pfizer’s Bavencio flunks head and neck cancer trial

https://pharmaphorum.com/news/merck-pfizers-bavencio-flunks-head-and-neck-cancer-trial/

AZ’s cediranib falls short again in ovarian cancer combination

AstraZeneca and Merck & Co’s latest attempt to revive an old pipeline drug cediranib has failed as it

AZ’s cediranib falls short again in ovarian cancer combination

https://pharmaphorum.com/news/azs-cediranib-falls-short-again-in-ovarian-cancer-combination/

Takeda’s Ninlaro falls short in first line multiple myeloma

Takeda’s Ninlaro (ixazomib) has fallen short in a late-stage study testing it in combination with Bristol-Myers Squibb/Celgene’s Revlimid

Takeda’s Ninlaro falls short in first line multiple myeloma

https://pharmaphorum.com/news/takedas-ninlaro-falls-short-in-first-line-multiple-myeloma/

See all

Views & analysis

Macrophage Pharma goes for gold with new funding round

Richard Staines spoke with Soren Bregenholt, the new CEO of Macrophage Pharma, about the company’s strategy encompassing both

Macrophage Pharma goes for gold with new funding round

https://pharmaphorum.com/r-d/views-analysis-r-d/macrophage-pharma-goes-for-gold-with-new-funding-round/

Helsinn’s Riccardo Braglia on the patient perspective in cancer care

Swiss cancer care company Helsinn has become unique in the industry by remaining a family business over three

Helsinn’s Riccardo Braglia on the patient perspective in cancer care

https://pharmaphorum.com/views-analysis-oncology/helsinns-riccardo-braglia-patient-perspective-cancer-care/

Antibody-drug conjugates on the march

One of AstraZeneca’s most decisive moves last year came in March, when it signed a multi-billion dollar deal

Antibody-drug conjugates on the march

https://pharmaphorum.com/views-analysis-oncology/antibody-drug-conjugates-on-the-march/

See all

Debates & Insights

Cost & Management of Oncology Combination Regimens

Overview Oncology treatment increasingly involves combinations of novel oral and biologic drugs. While combo approaches aren’t new, there

Cost & Management of Oncology Combination Regimens

https://pharmaphorum.com/oncology/cost-management-of-oncology-combination-regimens/

Cancer, genomics and personalised medicine: Modelling oncology’s future

Overview The prevalence of cancer is currently predicted to be higher than ever. Current statistics show 1 in

Cancer, genomics and personalised medicine: Modelling oncology’s future

https://pharmaphorum.com/oncology/cancer-genomics-and-personalised-medicine-modelling-the-future-of-oncology/

11/06/2017

Improving Outcomes Through Industry Partnership – Learnings from the Cancer Vanguard

A unique example of partnership working across the health system, focusses on the service at large, not just the pill, and uses leading-edge data analytics to analyse, benchmark and visualise the current state of the cancer pathways within the Cancer Vanguard Trusts. Furthermore, it encompasses multiple aspects of the service provision ranging from patient outcomes and experiences, the flow of treatment and the usage of medicine in order to inform an evidence-based and patient-centric approach to service redesign and resource optimisation.

Improving Outcomes Through Industry Partnership – Learnings from the Cancer Vanguard

https://pharmaphorum.com/debates-insight-oncology/improving-outcomes-through-industry-partnership-learnings-from-the-cancer-vanguard/

See all

Partner Content

Q&A with SKAN AG speaker released for HPAPI 2020

HPAPI Speaker Interview

Q&A with SKAN AG speaker released for HPAPI 2020

https://pharmaphorum.com/partner-content/qa-with-skan-ag-speaker-released-forhpapi-2020/

Attendee List Released for SMi’s 9th Annual RNA Therapeutics

RNA Therapeutics

Attendee List Released for SMi’s 9th Annual RNA Therapeutics

https://pharmaphorum.com/partner-content-oncology/attendee-list-released-for-smis-9th-annual-rna-therapeutics/

RNA Therapeutics conference will take place in just 4 weeks!

4 Weeks Until RNA Therapeutics

RNA Therapeutics conference will take place in just 4 weeks!

https://pharmaphorum.com/partner-content-oncology/rna-therapeutics-conference-will-take-place-in-just-4-weeks/

See all

Search

Advanced Search

Trending